Last reviewed · How we verify
Metformin and Evogliptin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Metformin and Evogliptin (Metformin and Evogliptin) — Dong-A ST Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metformin and Evogliptin TARGET | Metformin and Evogliptin | Dong-A ST Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metformin and Evogliptin CI watch — RSS
- Metformin and Evogliptin CI watch — Atom
- Metformin and Evogliptin CI watch — JSON
- Metformin and Evogliptin alone — RSS
Cite this brief
Drug Landscape (2026). Metformin and Evogliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-and-evogliptin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab